2025
Cutaneous lupus features specialized stromal niches and altered retroelement expression
Gehlhausen J, Kong Y, Baker E, Ramachandran S, Koumpouras F, Ko C, Vesely M, Little A, Damsky W, King B, Iwasaki A. Cutaneous lupus features specialized stromal niches and altered retroelement expression. Journal Of Investigative Dermatology 2025 PMID: 40409678, DOI: 10.1016/j.jid.2025.04.033.Peer-Reviewed Original ResearchRetroelement expressionCGAS-STING pathwayRIG-IType I interferonCutaneous lupusCGAS-STINGElevated expression of genesPathway enrichment analysisI interferonExpression of genesResponse to type I interferonsLupus skinRetroelement familiesInterferon-stimulated genesNucleic acid signalsApoptotic signalingSingle-cell RNAMultiple cell typesAcid signalingEnrichment analysisInflammatory cell recruitmentType II interferonInflammatory skin diseaseTumor necrosis factorCell typesCerebrospinal fluid immune phenotyping reveals distinct immunotypes of myalgic encephalomyelitis/chronic fatigue syndrome.
Bastos V, Greene K, Tabachnikova A, Bhattacharjee B, Sjögren P, Bertilson B, Reifert J, Zhang M, Kamath K, Shon J, Gehlhausen J, Guan L, VanElzakker M, Proal A, Bragée B, Iwasaki A. Cerebrospinal fluid immune phenotyping reveals distinct immunotypes of myalgic encephalomyelitis/chronic fatigue syndrome. The Journal Of Immunology 2025 PMID: 40373264, DOI: 10.1093/jimmun/vkaf087.Peer-Reviewed Original ResearchMyalgic encephalomyelitis/chronic fatigue syndromeCerebrospinal fluidImmune phenotypeFatigue syndromeMatched healthy control subjectsAssessed plasma samplesMultiplex analysis of cytokinesHealthy control subjectsAnalysis of cerebrospinal fluidAnalysis of cytokinesTreatment developmentClinical presentationSymptom presentationMultiorgan diseaseInflammatory profileControl subjectsPathophysiological mechanismsMatrix metalloproteinase profilesDisease subgroupsME/CFS participantsClinical questionnaireMatrix metalloproteinasesMetalloproteinase profilesHigh-throughput microarrayPlasma samplesMucosal unadjuvanted booster vaccines elicit local IgA responses by conversion of pre-existing immunity in mice
Kwon D, Mao T, Israelow B, Santos Guedes de Sá K, Dong H, Iwasaki A. Mucosal unadjuvanted booster vaccines elicit local IgA responses by conversion of pre-existing immunity in mice. Nature Immunology 2025, 26: 908-919. PMID: 40360777, DOI: 10.1038/s41590-025-02156-0.Peer-Reviewed Original ResearchMucosal immunityIgA responsesMemory CD4+ T cellsInduce robust mucosal immunitySARS-CoV-2 spike proteinCD4+ T cellsLocal protective immune responseRobust mucosal immunityRespiratory tractMRNA-LNP vaccinesIgA-secreting plasma cellsB cell recruitmentInduce mucosal immunityPre-existing immunityProtective immune responsesLower respiratory tractRecombinant SARS-CoV-2 spike proteinLocal IgA responseIntranasal boosterMucosal boostingIntranasal boostSpike proteinMRNA-LNPChemokines CXCL9T cellsImpact of COVID-19 vaccination on symptoms and immune phenotypes in vaccine-naïve individuals with Long COVID
Grady C, Bhattacharjee B, Silva J, Jaycox J, Lee L, Silva Monteiro V, Sawano M, Massey D, Caraballo C, Gehlhausen J, Tabachnikova A, Mao T, Lucas C, Peña-Hernandez M, Xu L, Tzeng T, Takahashi T, Herrin J, Güthe D, Akrami A, Assaf G, Davis H, Harris K, McCorkell L, Schulz W, Griffin D, Wei H, Ring A, Guan L, Dela Cruz C, Krumholz H, Iwasaki A. Impact of COVID-19 vaccination on symptoms and immune phenotypes in vaccine-naïve individuals with Long COVID. Communications Medicine 2025, 5: 163. PMID: 40346201, PMCID: PMC12064684, DOI: 10.1038/s43856-025-00829-3.Peer-Reviewed Original ResearchSpike protein-specific IgGProtein-specific IgGSelf-antigensImmune response to COVID-19 vaccinationCOVID-19 vaccineAntibody responseResponse to COVID-19 vaccinationT cell expansionSARS-CoV-2-specific antibody responsesAssociated with no improvementLong COVIDAssociated with symptom improvementChest painCirculating cytokinesImmune phenotypeProspective studyImmune featuresTransient improvementPrimary seriesVaccine doseHerpes virusImmune responseSymptom improvementSignificant elevationImpact of COVID-19 vaccinationNirmatrelvir–ritonavir versus placebo–ritonavir in individuals with long COVID in the USA (PAX LC): a double-blind, randomised, placebo-controlled, phase 2, decentralised trial
Sawano M, Bhattacharjee B, Caraballo C, Khera R, Li S, Herrin J, Christian D, Coppi A, Warner F, Holub J, Henriquez Y, Johnson M, Goddard T, Rocco E, Hummel A, Mouslmani M, Hooper W, Putrino D, Carr K, Charnas L, De Jesus M, Nepert D, Abreu P, Ziegler F, Spertus J, Iwasaki A, Krumholz H. Nirmatrelvir–ritonavir versus placebo–ritonavir in individuals with long COVID in the USA (PAX LC): a double-blind, randomised, placebo-controlled, phase 2, decentralised trial. The Lancet Infectious Diseases 2025 PMID: 40188838, DOI: 10.1016/s1473-3099(25)00073-8.Peer-Reviewed Original ResearchPhysical health summary scoreBaseline to dayAdverse eventsNirmatrelvir-ritonavirSARS-CoV-2 infectionDouble-blindStudy drug-related treatment-emergent adverse eventsDrug-related treatment-emergent adverse eventsTreatment-emergent adverse eventsIntention-to-treat populationWeek 6Baseline to week 6Documented SARS-CoV-2 infectionActive liver diseaseEffective pharmacological interventionsLong COVIDAcute medical illnessSafety populationPatient-Reported Outcomes Measurement Information SystemEarly treatment terminationRenal impairmentTreat long-COVIDPlacebo-controlledEfficacy endpointRandomised controlled trialsMIF as an oncogenic driver of low‐heterogeneity melanomas
Tran T, Sánchez‐Zuno G, Kulkarni R, Kluger H, Bucala R. MIF as an oncogenic driver of low‐heterogeneity melanomas. Molecular Oncology 2025, 19: 1295-1298. PMID: 40131169, PMCID: PMC12077282, DOI: 10.1002/1878-0261.70031.Peer-Reviewed Original ResearchConceptsMacrophage migration inhibitory factorImproving therapeutic outcomesMigration inhibitory factorPotential therapeutic utilityImmune landscapeMelanoma clonesImmune escapeT cellsImmunoregulatory cytokinesTumor heterogeneityTumor progressionOncogenic driversPathway inhibitorTherapeutic outcomesTumor evolutionInhibitory factorCell proliferationMelanomaTumorCellsAntagonistCytokinesPredicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer via interpretable multimodal deep learning
Bai Z, Osman M, Brendel M, Tangen C, Flaig T, Thompson I, Plets M, Scott Lucia M, Theodorescu D, Gustafson D, Daneshmand S, Meeks J, Choi W, Dinney C, Elemento O, Lerner S, McConkey D, Faltas B, Wang F. Predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer via interpretable multimodal deep learning. Npj Digital Medicine 2025, 8: 174. PMID: 40121304, PMCID: PMC11929913, DOI: 10.1038/s41746-025-01560-y.Peer-Reviewed Original ResearchMuscle-invasive bladder cancerResponse to neoadjuvant chemotherapyNeoadjuvant chemotherapyBladder cancerPredicting response to neoadjuvant chemotherapyOptimal treatment strategyImprove patient survivalImproving clinical outcomesGene expression profilesBladder preservationPredictive biomarkersPatient survivalUnnecessary treatmentClinical outcomesTreatment responseRNA sequencingTumor heterogeneityTreatment strategiesClinical trialsGene signatureExpression profilesMolecular determinantsCancerChemotherapyBuilding accurate predictive modelsMatrix-producing neutrophils populate and shield the skin
Vicanolo T, Özcan A, Li J, Huerta-López C, Ballesteros I, Rubio-Ponce A, Dumitru A, Nicolás-Ávila J, Molina-Moreno M, Reyes-Gutierrez P, Johnston A, Martone C, Greto E, Quílez-Alvarez A, Calvo E, Bonzon-Kulichenko E, Álvarez-Velez R, Chooi M, Kwok I, González-Bermúdez B, Malleret B, Espinosa F, Zhang M, Wang Y, Sun D, Zhen Chong S, El-Armouche A, Kim K, Udalova I, Greco V, Garcia R, Vázquez J, Dopazo A, Plaza G, Alegre-Cebollada J, Uderhardt S, Ng L, Hidalgo A. Matrix-producing neutrophils populate and shield the skin. Nature 2025, 1-9. PMID: 40108463, DOI: 10.1038/s41586-025-08741-5.Peer-Reviewed Original ResearchRepertoire of proteinsExtracellular matrixInnate immune systemPopulation of neutrophilsImmune diversityPromote barrier functionBacterial invasionInnate immune cellsTGFB signalingForeign moleculesPhysical barrierRing formationBarrier functionImmune systemEnvironmental threatsDefenceDiverse strategiesToxic chemicalsNaive skinTGFBImmune cellsBacteriaNeutrophilsEnzymeProteinSpatial transcriptomics reveals differential inflammatory pathways in discoid lupus erythematosus and lichen planus
Kidacki M, Cho C, Lopez-Giraldez F, Breidbart R, Jaiswal A, Lee M, Chowdhury S, Damsky W, Chen L, Vesely M. Spatial transcriptomics reveals differential inflammatory pathways in discoid lupus erythematosus and lichen planus. Journal Of Investigative Dermatology 2025 PMID: 40113031, DOI: 10.1016/j.jid.2025.02.148.Peer-Reviewed Original ResearchA Disproportionality Analysis on Benzoyl Peroxide and its Risk of Malignancy using the FDA Adverse Event Reporting System
Yang K, Czyz S, Zuberi R, Kreutz J, Bunick C, Jafarian F. A Disproportionality Analysis on Benzoyl Peroxide and its Risk of Malignancy using the FDA Adverse Event Reporting System. Journal Of Investigative Dermatology 2025 PMID: 40058570, DOI: 10.1016/j.jid.2025.02.139.Peer-Reviewed Original ResearchPhase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases.
Weiss S, Djureinovic D, Wei W, Tran T, Austin M, Markowitz J, Eroglu Z, Khushalani N, Hegde U, Cohen J, Sznol M, Anderson G, Johnson B, Piteo C, Mahajan A, Adeniran A, Jilaveanu L, Goldberg S, Chiang V, Forsyth P, Kluger H. Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases. Journal Of Clinical Oncology 2025, jco2402219. PMID: 40048689, DOI: 10.1200/jco-24-02219.Peer-Reviewed Original ResearchMelanoma brain metastasesOverall survivalBrain metastasesAnti-vascular endothelial growth factor therapyMedian intracranial progression-free survivalFour-year OS ratesIntracranial progression-free survivalResponse rateCirculating angiopoietin-2Median overall survivalTrial of pembrolizumabYears of pembrolizumabDose of bevacizumabProgression-free survivalPhase II trialGrowth factor therapyAdverse event ratesAssociated with responseOS ratesPD-1Radiation necrosisLocal therapyOn-therapyMetastatic tumorsFactor therapyInvestigation of the protein corona and biodistribution profile of polymeric nanoparticles for intra-amniotic delivery
Lynn A, Shin K, Eaton D, Rose M, Zhang X, Ene M, Grundler J, Deschenes E, Rivero R, Bracaglia L, Glazer P, Stitelman D, Saltzman W. Investigation of the protein corona and biodistribution profile of polymeric nanoparticles for intra-amniotic delivery. Biomaterials 2025, 320: 123238. PMID: 40064138, DOI: 10.1016/j.biomaterials.2025.123238.Peer-Reviewed Original ResearchAmniotic fluidProtein corona formationProtein coronaIntra-amniotic deliveryNP delivery systemPEGylated nanoparticlesSurface polyethylene glycolPoly(lactic-co-glycolic acidProtein corona compositionLung cells in vitroCorona formationPLA-PEG nanoparticlesNon-PEGylated nanoparticlesCells in vitroLevels of albuminFetal bowelFetal lungFetal organsNP biodistributionPoly(lactic-acidDense brush conformationCorona compositionPolyvinyl alcoholBiodistribution profileCellular associationDeucravacitinib in plaque psoriasis: Four‐year safety and efficacy results from the Phase 3 POETYK PSO‐1, PSO‐2 and long‐term extension trials
Armstrong A, Lebwohl M, Warren R, Sofen H, Morita A, Paul C, Papp K, Colombo M, Scotto J, Vaile J, Zhuo J, Vritzali E, Berger V, Schroeder G, Banerjee S, Thaçi D, Strober B. Deucravacitinib in plaque psoriasis: Four‐year safety and efficacy results from the Phase 3 POETYK PSO‐1, PSO‐2 and long‐term extension trials. Journal Of The European Academy Of Dermatology And Venereology 2025 PMID: 40045918, DOI: 10.1111/jdv.20553.Peer-Reviewed Original ResearchLong-term extension trialsLong-term extensionModerate to severe plaque psoriasisSevere plaque psoriasisPlaque psoriasisAdverse eventsTyrosine kinase 2Person yearsData cut-offYear of treatmentAdverse cardiovascular eventsTreatment of adultsPatient-reported outcomesSystemic therapyHerpes zosterSafety profileVenous thromboembolismDeucravacitinibCardiovascular eventsEfficacy resultsPatientsPsoriasisOutcome ratesExtension trialParent trialSystemic Therapies for Pediatric Alopecia Areata
Kalil L, Welch D, Heath C, Craiglow B. Systemic Therapies for Pediatric Alopecia Areata. Pediatric Dermatology 2025, 42: 36-42. PMID: 40044621, DOI: 10.1111/pde.15822.Peer-Reviewed Original ResearchConceptsAlopecia areataSystemic therapyPediatric alopecia areataAutoimmune hair loss disorderJanus kinase inhibitorsHair loss disorderComorbid atopyOral minoxidilLong-term useSystemic corticosteroidsTopical therapySystemic treatmentPediatric AACase reportAdjunctive treatmentMild diseaseKinase inhibitorsImmunomodulatory medicinesTherapyExtensive involvementAdverse effectsNarrative reviewAreataPatientsTreatmentIMPACT OF TUMOR STAGE IN PATIENTS WITH BCG-UNRESPONSIVE NMIBC WHO UNDERGO UPFRONT RADICAL CYSTECTOMY: A LARGE MULTI-INSTITUTIONAL STUDY
Annapureddy D, Taylor J, Howard J, Tan W, McElree I, Davaro F, Yim K, Harrington S, Dyer E, Black A, Kanabur P, Roumiguié M, Lerner S, Black P, Raman J, Preston M, Steinberg G, Huang W, Li R, Packiam V, O'Donnell M, Kamat A, Woldu S, Lotan Y. IMPACT OF TUMOR STAGE IN PATIENTS WITH BCG-UNRESPONSIVE NMIBC WHO UNDERGO UPFRONT RADICAL CYSTECTOMY: A LARGE MULTI-INSTITUTIONAL STUDY. Urologic Oncology Seminars And Original Investigations 2025, 43: 81. DOI: 10.1016/j.urolonc.2024.12.204.Peer-Reviewed Original ResearchBCG-unresponsive NMIBCNon-muscle invasive bladder cancerCarcinoma in situImpact of tumor stageBCG-unresponsiveRadical cystectomyUpfront RCCancer-specific mortalityOncological outcomesTumor stageT1 patientsAll-cause mortalityTA patientsPathological outcomesPapillary diseaseHigh risk of recurrenceBCG-unresponsive diseaseClinical stage tumorsUpfront radical cystectomyClinical tumor stageNode-positive diseaseCompare oncologic outcomesInvasive bladder cancerT1 stage tumorsKaplan-Meier methodIMPROVED OUTCOMES IN BCG-UNRESPONSIVE BLADDER CANCER PATIENTS WITH NON-INVASIVE DISEASE UNDERGOING BLADDER SPARING THERAPY COMPARED TO T1 DISEASE: RESULTS FROM AN INTERNATIONAL COHORT
Annapureddy D, Taylor J, Howard J, Tan W, McElree I, Davaro F, Yim K, Harrington S, Dyer E, Black A, Kanabur P, Roumiguié M, Lerner S, Black P, Raman J, Preston M, Steinberg G, Huang W, Li R, Packiam V, O'Donnell M, Kamat A, Woldu S, Lotan Y. IMPROVED OUTCOMES IN BCG-UNRESPONSIVE BLADDER CANCER PATIENTS WITH NON-INVASIVE DISEASE UNDERGOING BLADDER SPARING THERAPY COMPARED TO T1 DISEASE: RESULTS FROM AN INTERNATIONAL COHORT. Urologic Oncology Seminars And Original Investigations 2025, 43: 80-81. DOI: 10.1016/j.urolonc.2024.12.203.Peer-Reviewed Original ResearchBCG-unresponsive NMIBCNon-muscle invasive bladder cancerBladder sparing therapyAll-cause mortalityOncological outcomesRadical cystectomyCancer-specific mortalityNon-invasive diseaseBCG-unresponsiveBladder cancerPathological outcomesT1 diseaseT1 patientsCIS patientsMedian timeProgression to muscle-invasive bladder cancerBCG-unresponsive NMIBC patientsImpact of pathological stageImpact of tumor stageInternational cohortMuscle-invasive bladder cancerAssociated with significant morbiditySingle-institution seriesHeterogeneous group of patientsCompare oncologic outcomesIntroduction
Branham G, Dover J, Khetarpal S, Ramanadham S, Wulc A. Introduction. Advances In Cosmetic Surgery 2025 DOI: 10.1016/j.yacs.2025.02.003.Peer-Reviewed Original ResearchReal-world outcomes with T-VEC in patients with anti-PD-1 resistant in-transit disease from melanoma and Merkel cell carcinoma
Su D, McNamara M, Kaszycki M, Frey A, Ishizuka J, Costa P, Tran T, Kluger H, Clune J, Weiss S, Olino K. Real-world outcomes with T-VEC in patients with anti-PD-1 resistant in-transit disease from melanoma and Merkel cell carcinoma. Surgical Oncology Insight 2025, 2: 100120. DOI: 10.1016/j.soi.2024.100120.Peer-Reviewed Original ResearchMerkel cell carcinomaMerkel cell carcinoma casesT-VECCell carcinomaMedian numberAnti-PD-1 blockadeStage IIIB-IV melanomaAdvanced Merkel cell carcinomaIn-transit melanomaIn-transit diseaseICI therapyTalimogene laherparepvecAdvanced melanomaCancer immunotherapyMetastatic sitesPartial responseIn-transitRegional metastasesMedian ageGrade 3Adverse eventsTreatment cyclesDisease progressionMelanomaPatientsINCIDENCE AND PATHOLOGIC OUTCOMES OF CYSTECTOMY IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN-UNRESPONSIVE NON–MUSCLE-INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU FOLLOWING TREATMENT WITH NADOFARAGENE FIRADENOVEC-VNCG
Narayan V, Boorjian S, Crispen P, Kamat A, Gomella L, Kates M, Karsh L, Master V, Richards K, Lerner S, Kim E, Inman B, Lane B, Schuckman A, Krupski T, Bardot S, Montgomery J, Busby J, Luchey A, Williams M, Agarwal P, Rehm D, Jakobsen J, Juul K, Dinney C. INCIDENCE AND PATHOLOGIC OUTCOMES OF CYSTECTOMY IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN-UNRESPONSIVE NON–MUSCLE-INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU FOLLOWING TREATMENT WITH NADOFARAGENE FIRADENOVEC-VNCG. Urologic Oncology Seminars And Original Investigations 2025, 43: 86. DOI: 10.1016/j.urolonc.2024.12.217.Peer-Reviewed Original ResearchBCG-unresponsive NMIBCNon-muscle-invasive bladder cancerCystectomy-free survivalCarcinoma in situNadofaragene firadenovecPhase 3 studyCR statusBladder cancerKaplan-MeierPathological outcomesVector-based gene therapyMedian follow-up timeBladder-sparing optionsHigh-grade recurrenceYears of follow-upRate of upstagingKaplan-Meier (KMAssociated with morbidityData cutoffImmediate cystectomyTransurethral resectionPapillary tumorsOpen-labelDefinitive treatmentEfficacy analysis437 Spatial Whole Transcriptomic Analysis Reveals Differential Gene Expression in Epithelial and Mesenchymal Components of Primary Cutaneous Carcinosarcomas
Hernandez S, Galan A, Lu W, Lermi N, Aung P, Kostousov L, Barnes S, Khan K, Chen K, Soto L, Nagarajan P. 437 Spatial Whole Transcriptomic Analysis Reveals Differential Gene Expression in Epithelial and Mesenchymal Components of Primary Cutaneous Carcinosarcomas. Laboratory Investigation 2025, 105: 102665. DOI: 10.1016/j.labinv.2024.102665.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply